GT Biopharma, Inc.: Business Overview, Financials & Competitive Analysis
GT Biopharma, Inc. scores 4/10 on the AskCyborg Cyborg Score (Challenged). High-risk NK cell immunotherapy play with differentiated TriKE platform, but survival depends on clinical progress and capital restructuring. GT Biopharma is a pre-revenue clinical-stage biotech with early-phase programs and limited financial resources. The company faces near-term delisting risk from Nasdaq due to low stock price and limited cash runway.
What is GT Biopharma, Inc.'s industry? GT Biopharma, Inc. (gtbiopharma.com) operates in Oncology Drugs. AskCyborg classifies GT Biopharma, Inc. under Oncology Drugs in its company registry.
GT Biopharma is a clinical-stage immuno-oncology company focused on developing innovative therapies based on its proprietary NK cell engager (TriKE®) technology. The TriKE platform is designed to harness and enhance t...
Cyborg Score thesis
High-risk NK cell immunotherapy play with differentiated TriKE platform, but survival depends on clinical progress and capital...
Read the full analyst-debate transcript →Get the Latest GT Biopharma, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGT Biopharma, Inc. Overview
Pro stress-test →GT Biopharma is a clinical-stage immuno-oncology company focused on developing innovative therapies based on its proprietary NK cell engager (TriKE®) technology. The TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient's immune system's natural killer cells.
Strategic Profile
Pro stress-test →Its lead clinical candidate, GTB-3650, is in a Phase 1 dose-escalation trial for relapsed or refractory CD33-expressing hematologic malignancies, while GTB-5550 targets B7-H3–expressing solid tumors and has reached the IND submission stage. However, in November 2025, the company received a Nasdaq notice that its common stock had closed below $1 per share for 30 consecutive business days, indicating non-compliance with the minimum bid price requirement for continued listing.
Competitive Landscape
Pro stress-test →GT Biopharma operates in the NK cell-based immunotherapy segment, competing with other emerging biotech firms developing engineered NK and T-cell platforms. Direct competitors include Fate Therapeutics and Juno Therapeutics (Celgene/Bristol Myers Squibb subsidiary), though GT's TriKE approach differs from traditional CAR-NK and CAR-T modalities. The company faces competition from larger pharmaceutical immunotherapy programs at Merck, Roche, and others pursuing similar oncology indications.
Industry Context
GT Biopharma, Inc. operates in Oncology Drugs.
Key facts
Founded: 1998 (as OXIS International) · Headquarters: San Francisco, US · Employees: Unknown · Revenue: Null · Market cap: ~$0.09B (based on June 2026 stock price ~$0.42)